Document is current
Any future updates will be listed below
-
Authors
Yadollahi, Pedram
McCord, Kelli A.
Li, Yang
Dayoub, Hussam
Saab, Kalil
Essien, Fonma
Hyslop, Sean
Kan, Emerald
Ahmed, Kazi M.
Kirby, Parker R.
Putluri, Vasanta
Ambati, Chandra Shekar. R.
Kami Reddy, Karthik Reddy
Castro, Patricia https://orcid.org/0000-0001-5286-8037
Skinner, Heath D.
Coarfa, Cristian
Decker, William K.
Osman, Abdullah A.
Patel, Rutulkumar
Myers, Jeffrey N. https://orcid.org/0000-0003-4767-3408
Lai, Stephen Y. https://orcid.org/0000-0001-8301-7286
Putluri, Nagireddy
Johnson, Faye M.
Frederick, Mitchell J. https://orcid.org/0000-0002-0932-8809
Hudson, William H. https://orcid.org/0000-0002-2513-1213
Sandulache, Vlad C. https://orcid.org/0000-0002-9205-385X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA280980)
- License Information
-
More Information
Article History
Received: 13 February 2025
Revised: 5 August 2025
Accepted: 2 September 2025
First Online: 6 October 2025
Competing interests
: The authors report no conflicts of interests relevant to the work summarized in the current manuscript. VCS is a consultant and equity holder in Femtovox Inc. WKD declares an ownership stake in Diakonos Research, Ltd. and financial compensation from Diakonos Oncology Corporation. WKD also declares a financial relationship with APAC Biotech, Pvt, Ltd from 2015 to 2020.
: All work summarized herein was approved by the Baylor College of Medicine Institutional Animal Care and Use Committee (IACUC; protocol AN 7291). All methods were performed in accordance with the relevant guidelines and regulations.
